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high voluntary enrolment rate in the NRCMS a number of issues have been iden-
tified in the survey. Three key remedial actions in health financing, planning and
management to counteract the identified issues are proposed: 1) Enacting legisla-
tion and setting up a risk fund to ensure sustainability of the NRCMS; 2)The main
rights and responsibilities of related parties in the NRCMS should be clarified to
improve the incentive mechanism; and 3) Integrate disease prevention and the
reform of township hospitals.
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OBJECTIVES: To estimate the incidences of hospitalizations for statin-related ad-
verse events (AEs) and further evaluate the influence of the concomitant use of
fibrates or cytochrome P450 (CYP) 3A4 inhibitors on the risks of AEs in patients
initiating statin treatments. METHODS: A retrospective cohort study design was
employed with analyses from the Taiwan National Health Insurance Research Da-
tabase between January 1, 2000 and December 31, 2007. The study cohort com-
prised patients initially treated with statins, and was followed to observe the oc-
currence of hospitalizations for statin-associated AEs, including myopathy, renal
adverse events, hepatotoxic events and acute pancreatitis. Use of statins was fur-
ther categorized into three groups to examine the effect of concomitant use of the
interacting drugs: statin-fibrate combination, statin-CYP3A4 inhibitor combina-
tion, and statin monotherapy. Poisson regressions were used to estimate the indi-
vidual incidences and incidence rate ratios (IRRs) of hospitalization events for the
combined therapies versus statin monotherapy. RESULTS: A total of 53,594 statin
initiators were identified as the study cohort, with atorvastatin and lovastatin
being observed as the most commonly prescribed statins. The proportion of statin
initiators concomitantly treated with fibrates and CYP3A4 inhibitors was 7.1% and
14.3%, respectively. Overall, the highest incidence occurred in renal adverse events
(36.8/10,000 person-years), followed by hepatotoxic events, acute pancreatitis, and
myopathy. A similar ranking order of the incidences was observed across the three
groups. Compared to statin monotherapy, combination therapy of statins with the
interacting medications increased the risks of overall AEs (statin-fibrate combina-
tion: adjusted IRR, 2.01; 95% CI, 1.21-3.32; statin-CYP3A4 inhibitor combination:
adjusted IRR, 2.29; 95% CI, 1.73-3.02). CONCLUSIONS: Renal toxicity is found to be
the most frequently occurring AE during statin treatments. Concomitant use of
statins with fibrates or CYP3A4 inhibitors increases the risks of statin-associated
AEs, which warrants caution for close monitoring of adverse symptoms when st-
atins are used concurrently with the potential interacting drugs.
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OBJECTIVES: To evaluate the association between use of antipsychotics and risk of
stroke in patients with cardiovascular diseases (CVDs).METHODS: This was a ret-
rospective nested case-control study analyzing data from the National Health In-
surance Research Database in Taiwan. A cohort of all patients with CVDs initiating
an antipsychotic was identified during January 1, 1998 and December 31, 2006.
Cases were defined as those with hospitalizations for stroke (ICD9-CM codes 430-
438, A-code A29), and the date of stroke admission was referred as the index date.
Using the incidence density sampling approach, each case was matched to ten
randomly-selected controls on age ( 5 years), sex and cohort entry date ( 365
days). Controlswere assigned the same index date as their corresponding case. Use
of antipsychotics was measured during a six-month period before the index date
and categorized into typical or atypical class. Conditional logistic regressions were
used to estimate odds ratios (ORs).RESULTS:The study cohort comprised 6773 CVD
patients, fromwhich 533 cases and 5057matched controls were identified. Any use
of atypical antipsychotics was associated with an increased risk of stroke when
compared with typical antipsychotics (adjusted OR, 1.46; 95 % CI, 1.01-2.10). Addi-
tionally, the comparative risk was increased to a greater extent as atypical antip-
sychotics were prescribed within 90 days before the index date (adjusted OR, 1.94;
95% CI, 1.34-2.83). Further stratified analyses indicated that any use of atypical
antipsychotics was associated with a 1.55-fold increased risk of stroke in the el-
derly population. CONCLUSIONS: Use of atypical antipsychotics is associated with
an increased risk of stroke relative to typical antipsychotics among patients with
CVDs, and the risk is further increased as atypical antipsychotics are prescribed
more currently. Clinicians should be aware of the stroke risk while prescribing
antipsychotics for patients with underlying CVDs, especially in the elderly.
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OBJECTIVES: To determine the outcome and the prognostic factors among severe
sepsis and septic shock (SS&SK) survivors one year after hospital discharge.
METHODS: This was a retrospective and cross-sectional study of patients (18
years) admitted 24 hours between April 2007 and March 2010 for the first time to
themedical-surgical and trauma intensive care unit (ICU) of a tertiary hospital and
discharged from the hospital alive. For patients withmore than one ICU admission
within the same hospitalization, only first ICU admission was counted. Data ob-
tained from an electronic ICU database, hospital information system and medical
records. Additionally, We conducted telephonic interviews to evaluate vital status
and performance at one year of hospital discharge using KARNOFSKY PERFOR-
MANCE STATUS SCALE. Patients who had cardiac arrest were excluded from the
study. RESULTS: The overall mortality rate was 35%. One-third (31%) of who were
still survive at one year post hospital discharge, suffer from significant (P0.05)
impairment of performance status. SS&SK survivors who had CHF had 3.4 times
higher risk to die as compared to who did not had CHF. Pre-sepsis performance
status and CHF were the independent prognostic factors for poor hospital out-
comes on long term post hospital discharge in SS&SK survivors. CONCLUSIONS:
About one third of patients die by one year, another one-third suffer from signifi-
cant impairment of performance status. Pre-sepsis performance status and CHF
were the independent prognostic factors in SS&SK survivors. This data highlights
the need for different strategies for caring of SS&SK survivors.
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OBJECTIVES: Thrombolytic therapy is widely accepted as a standard treatment for
patients diagnosed with ST-Elevated Acute Coronary Syndrome (ACS). Enoxaparin
has been the most commonly used medicine but its increased risk of bleeding is a
major concern. Fondaparinux has been available with a potentially better safety
profile, but there still no direct head to head study comparing these two agents.
This study aims to determine the comparative efficacy and safety of enoxaparin
and fondaparinux for treating ST-Elevated ACS using a network meta-analysis.
METHODS:We undertook a systematic review to identify studies from computer-
ized databases including Pubmed, Cochrane and Clinical Trial.gov. Inclusion crite-
ria are 1) RCT in STEMI patients receiving fibrinolytic agent, and 2) Using Enoxa-
parin or Fondaparinux. Efficacy outcome was death or myocardial re-infarction at
30 days, while safety outcome wasmajor bleeding event during in hospital or at 30
days. All studies were extracted independently by 2 reviewers. Heterogeneity was
tested using Q-statistics and I2 test. Indirect comparison based on a networkmeta-
analysis under a random-effects model was used to synthesize the comparison
between these 2 products. RESULTS: Seven studies were included in this study (6
compared Enoxaparin and UFH and 1 Compared Fondaparinux and UFH). The re-
sult of network meta-analysis indicated similar efficacy between fondaparinux
and enoxaparin (OR  1.12 (CI: 0.76-1.65), with the lower risk of major bleeding in
the fondaparinux group (OR  0.40 (CI: 0.17-0.96). There was no heterogeneity
revealed from Q-statistics and I2. CONCLUSIONS: Our study indicated that among
patients with STEACS receiving fibrinolytic agent, fondaparinux has similar effi-
cacy on death/myocardial infarction but statistically significant lower bleeding
event compared with enoxaparin. Fondaparinux seems to have favorable risk/
benefit profile compared with Enoxaparin when used in STEMI patients receiving
fibrinolytic agents.
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OBJECTIVES: Statins are the first-line drug therapy in the treatment of hypercho-
lesterolemia. The beneficial clinicalimpact of statins on the cardiovascular system
resultsnot only from their lipid-lowering action but also from their pleiotropic
effects. Recently, it has been suggested thatstatins can reduce blood pressure;
however the available data are still ambiguousand often conflicting. Therefore we
performed the meta-analysis to investigate the potential hypotensive action of
statins in patients with or without hypertension. METHODS: Data from Scopus,
PubMed,Web of Science, and the Cochrane Central Register of Controlled Trials for
years 1966 to October 2011 were searched for studies that investigated the effect of
statins on blood pressure either in normotensive or hypertensive subjects.
RESULTS: Finally themeta-analysis included 18 trials - 5628 subjects (4692 normo-
tensive, 936 hypertensive) randomized to receive either statins or placebo.The
standardized effect size of mean differences of systolic (DSBP) and diastolic blood
pressure (DDBP) in normotensive patients for ten included trials for statins therapy
was 0.006 (95%CI: -0.052-0.063; p0.84) and -0.03 (95%CI: -0.09-0.03; p0.3), respec-
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